Szymon Wojciech Kmiecik

Dr. Szymon Wojciech Kmiecik

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
Szymon Wojciech KmiecikSzymon Wojciech Kmiecik
Szymon Wojciech Kmiecik
MMMatthias Mayer
Matthias Mayer

3 June 2020 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
Szymon Wojciech KmiecikSzymon Wojciech Kmiecik
Szymon Wojciech Kmiecik
LBLaura Le Breton
Laura Le Breton
MMMatthias Mayer
Matthias Mayer
The heat shock response is a universal transcriptional response to proteotoxic stress orchestrated by heat shock transcription factor Hsf1 in all eukaryotic cells. Despite over 40 years of intense research, the mechanism of Hsf1 activity regulation remains poorly understood at the molecular level. In metazoa, Hsf1 trimerizes upon heat shock through a leucine‐zipper domain and binds to DNA. How Hsf1 is dislodged from DNA and monomerized remained enigmatic. Here, using purified proteins, we demonstrate that unmodified trimeric Hsf1 is dissociated from DNA in vitro by Hsc70 and DnaJB1. Hsc70 binds to multiple sites in Hsf1 with different affinities. Hsf1 trimers are monomerized by successive cycles of entropic pulling, unzipping the triple leucine‐zipper. Starting this unzipping at several protomers of the Hsf1 trimer results in faster monomerization. This process directly monitors the concentration of Hsc70 and DnaJB1. During heat shock adaptation, Hsc70 first binds to a high‐affinity site in the transactivation domain, leading to partial attenuation of the response, and subsequently, at higher concentrations, Hsc70 removes Hsf1 from DNA to restore the resting state.

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
Szymon Wojciech KmiecikSzymon Wojciech Kmiecik
Szymon Wojciech Kmiecik
KDKatarzyna Drzewicka
Katarzyna Drzewicka
FMFrauke Melchior
Frauke Melchior
MMMatthias Mayer
Matthias Mayer
The heat shock response (HSR) is a transcriptional program of organisms to counteract an imbalance in protein homeostasis. It is orchestrated in all eukaryotic cells by heat shock factor 1 (Hsf1). Despite very intensive research, the intricacies of the Hsf1 activation-attenuation cycle remain elusive at a molecular level. Posttranslational modifications belong to one of the key mechanisms proposed to adapt the Hsf1 activity to the needs of individual cells and phosphorylation of Hsf1 at multiple sites has attracted much attention. According to cell biological and proteomics data, Hsf1 is also modified by SUMO (small ubiquitin-like modifier) at several sites. How SUMOylation affects Hsf1 activity at a molecular level is still unclear. Here, we analyzed Hsf1 SUMOylation in vitro with purified components to address questions that could not be answered in cell culture models. In vitro Hsf1 is primarily conjugated at lysine 298 with a single SUMO, though we did detect low level SUMOylation at other sites. Different SUMO E3 ligases such as PIAS4 enhanced the efficiency of in vitro modification, but did not alter SUMO site preferences. We provide evidence that Hsf1 trimerization and phosphorylation at serines 303 and 307 increases SUMOylation efficiency, suggesting that Hsf1 is SUMOylated in its activated state. Hsf1 can be SUMOylated when DNA-bound, and SUMOylation of Hsf1 does neither alter DNA binding affinity nor does it affect Hsc70 and DnaJB1-mediated monomerization of Hsf1 trimers and concomitant dislocation from DNA. We propose that SUMOylation acts at the transcription level of the HSR.

30 July 2017 in Postępy Higieny I Medycyny Doświadczalnej
Verified
Journal Article
Open access
Szymon Wojciech KmiecikSzymon Wojciech Kmiecik
Szymon Wojciech Kmiecik
MKMateusz Adam Krzyscik
Mateusz Adam Krzyscik
BFBeata Filip-Psurska
Beata Filip-Psurska
JWJoanna Wietrzyk
Joanna Wietrzyk
JBJanusz Boratyński
Janusz Boratyński
TGtomasz goszczynski
tomasz goszczynski
Introduction: The use of hybrid molecules has become one of the most significant approaches in new cytotoxic drug design. This study describes synthesis and characterization of conjugates consisting of two well-known and characterized chemotherapeutic agents: methotrexate (MTX) and epirubicin (EPR). The synthesized conjugates combine two significant anticancer strategies: combinatory therapy and targeted therapy. These two drugs were chosen because they have different mechanisms of action, which can increase the anticancer effect of the obtained conjugates. MTX, which is a folic acid analog, has high cytotoxic properties and can serve as a targeting moiety that can reach folate receptors (FRs) overexpresing tumor cells. Combination of nonselective drugs such as EPR with MTX can increase the selectivity of the obtained conjugates, while maintaining the high cytotoxic properties.Materials and methods: Conjugates were purified by RP-HPLC and the structure was investigated by MS and MS/MS methods. The effect of the conjugates on proliferation of LoVo, LoVo/Dx, MCF-7 and MV-4-11 human cancer cell lines was determined by SRB or MTT assay.Results: The conjugation reaction results in the formation of monosubstituted (α, γ) and disubstituted MTX derivatives. In vitro proliferation data demonstrate that the conjugates synthesized in our study show lower cytotoxic properties than both chemotherapeutics used alone.Discussion: Epirubicin cytotoxicity was not observed in obtained conjugates. Effective drugs release after internalization needs further investigation

8 December 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Szymon Wojciech KmiecikSzymon Wojciech Kmiecik
Szymon Wojciech Kmiecik
JLJennifer Lewis
Jennifer Lewis
JSJonas Schwickert
Jonas Schwickert
HBHenrik Christian Breitenreicher
Henrik Christian Breitenreicher
MSMartin Ronald Sprick
Martin Ronald Sprick
JBJuergen Burhenne
Juergen Burhenne
Background: Ovarian cancer remains one of the leading causes of cancer-related mortality among women and constitutes a major unmet medical need. A common treatment-limiting factor for ovarian cancer patients is resistance to Poly(ADP-ribose) polymerase (PARP) inhibitors such as olaparib. Resistance mechanisms include restoration of functional homologous recombination repair, replication fork protection, PARP1 mutations, and increased drug efflux or metabolism. Understanding these cellular and molecular mechanisms is essential for developing more effective therapeutic strategies and improving patient outcomes. Methods: In this study, patient-derived ovarian cancer cells (OC12) in which resistance to olaparib was induced by exposing the cells to increasing concentrations of the drug over multiple treatment cycles were investigated. To compare intracellular olaparib levels in sensitive and resistant cell lines, a UPLC-MS/MS method to quantify olaparib in the range of 1–300 ng/mL was developed. Results: The method was validated for selectivity, calibration curve performance, carryover, dilution integrity, precision, accuracy, matrix effect, and recovery in accordance with ICH M10 guidelines for bioanalytical method validation. Our findings revealed no significant difference in olaparib levels between resistant and sensitive OC12 cells, excluding the involvement of efflux transporters or enhanced metabolism of olaparib in the resistant OC12 ovarian cancer cells. Conclusions: These results shift the future focus toward pharmacodynamic factors as key drivers of olaparib resistance in OC12 cells. Taken together, the developed UPLC-MS/MS analytical method can be successfully applied to quantify intracellular olaparib levels and investigate the potential contribution of drug efflux mechanisms or increased metabolic activity in cells resistant to olaparib treatment.

11 May 2023 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
Szymon Wojciech KmiecikSzymon Wojciech Kmiecik
Szymon Wojciech Kmiecik
QSQiaoni Shi
Qiaoni Shi
YCYe-Guang Chen
Ye-Guang Chen
JMJannis Moormann
Jannis Moormann
THTatjana M. Hildebrandt
Tatjana M. Hildebrandt
KKKyusik Q. Kim
Kyusik Q. Kim